| Literature DB >> 28038718 |
Dariusz Plicner1, Jarosław Stoliński2, Marcin Wąsowicz3, Bugusław Gawęda2, Hubert Hymczak4, Bogusław Kapelak5, Rafał Drwiła4, Anetta Undas6.
Abstract
OBJECTIVE: The impact of systemic inflammation on clinical outcomes after CABG surgery is still controversial. In this study, we evaluated the impact of the markers of inflammation, endothelial damage and platelet activation on clinical outcomes after on- and off-pump CABG.Entities:
Keywords: Cardiopulmonary bypass; Coronary artery bypass grafting; Inflammation
Mesh:
Substances:
Year: 2016 PMID: 28038718 PMCID: PMC5198874 DOI: 10.1016/j.ihj.2016.10.002
Source DB: PubMed Journal: Indian Heart J ISSN: 0019-4832
Baseline characteristics of CABG patients.
| Variable | All patients | Patients with CPB | Patients without CPB | |
|---|---|---|---|---|
| Age (years) | 64.9 ± 8.1 | 65.2 ± 8.2 | 63.5 ± 7.4 | 0.282 |
| Female, | 43 (22.5) | 35 (22.2) | 8 (24.2) | 0.794 |
| Peripheral vascular disease, | 31 (16.2) | 25 (15.8) | 6 (18.2) | 0.738 |
| Diabetes mellitus, | 59 (30.9) | 46 (29.1) | 13 (39.4) | 0.245 |
| Insulin, | 28 (14.7) | 22 (13.9) | 6 (18.2) | 0.529 |
| Hypertension, | 158 (82.7) | 127 (80.4) | 31 (93.9) | 0.061 |
| Hypercholesterolemia, | 126 (66.0) | 101 (63.9) | 25 (75.8) | 0.192 |
| Previous myocardial infarction, | 154 (80.6) | 128 (81.0) | 26 (78.8) | 0.769 |
| Previous PCI, | 23 (12.0) | 19 (12.0) | 4 (12.1) | 0.998 |
| Current smoking, | 54 (34.2) | 44 (32.6) | 10 (43.5) | 0.309 |
| COPD, | 11 (5.8) | 9 (5.7) | 2 (6.1) | 0.942 |
| Atrial fibrillation, | 11 (6.8) | 10 (7.2) | 1 (4.3) | 0.610 |
| BMI, kg/m2 | 28.0 ± 3.9 | 28.0 ± 3.9 | 28.0 ± 4.0 | 0.791 |
| LVEF, % | 52.0 ± 9.3 | 52.1 ± 9.4 | 51.3 ± 9.2 | 0.648 |
| EuroSCORE I | 2.9 ± 1.9 | 3.0 ± 1.9 | 2.6 ± 2.0 | 0.329 |
| Aspirin, | 38 (20.1) | 31 (19.9) | 7 (21.2) | 0.862 |
| ACE inhibitors, | 168 (88.0) | 137 (86.7) | 31 (93.9) | 0.246 |
| β-blockers, | 172 (90.1) | 141 (89.2) | 31 (93.9) | 0.412 |
| Lipid-lowering statin, | 171 (89.5) | 141 (89.2) | 30 (90.9) | 0.776 |
Values are displayed as mean ± standard deviation or number (percentage).
ACE, angiotensin-converting enzyme; BMI, body mass index; COPD, chronic obstructive pulmonary disease; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary interventions.
Operative and postoperative characteristics of CABG patients.
| Variable | All patients | Patients with CPB | Patients without CPB | |
|---|---|---|---|---|
| Aortic cross-clamp time, minutes | 40.1 ± 14.0 | 40.1 ± 14.0 | – | – |
| CPB time, minutes | 89.2 ± 32.2 | 89.2 ± 32.2 | – | – |
| Transfusion (red cells/platelets/plasma) ≥2 units, | 126 (66) | 105 (66.5) | 21 (63.6) | 0.137 |
| Postoperative drainage, mL | 700 (480–975) | 850 (540–1150) | 685 (480–920) | 0.017 |
| LCOS, | 13 (6.8) | 10 (6.3) | 3 (9.1) | 0.567 |
| PMI, | 19 (9.9) | 13 (8.2) | 6 (18.2) | 0.082 |
| ICU length of stay ≥2 days, | 82 (43.2) | 62 (39.2) | 20 (62.5) | 0.511 |
| In-hospital cardiovascular death, | 7 (3.7) | 6 (3.8) | 1 (3.0) | 0.831 |
Values are displayed as mean ± standard deviation, number (percentage) or median with 25th–75th percentiles inter-quartile range.
CPB, cardiopulmonary bypass; ICU, intensive care unit; LCOS, low cardiac output syndrome; PMI, postoperative myocardial infarction.
Changes of studied inflammatory response parameters in patients with analyzed clinical end-points.
| Variable | All patients | Patients with LCOS | Patients without LCOS | Patients with PMI | Patients without PMI | In-hospital death | Survivors | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline 8-iso-PGF2α, (pg/mL) | 358.6 ± 39.3 | 392.1 ± 56.2 | 356.1 ± 36.8 | 0.001 | 386.5 ± 52.5 | 355.5 ± 36.5 | <0.001 | 385.8 ± 53.9 | 357.0 ± 38.1 | 0.011 |
| 18–36 h post CABG 8-iso-PGF2α, (pg/mL) | 468.1 ± 43.4 | 526.2 ± 75.1 | 463.4 ± 36.4 | 0.015 | 505.3 ± 66.4 | 463.4 ± 37.4 | 0.017 | 543.4 ± 50.2 | 464.7 ± 40.4 | 0.021 |
| 5–7 days post CABG 8-iso-PGF2α, (pg/mL) | 417.0 ± 48.2 | 528.9 ± 58.9 | 409.3 ± 36.8 | 0.001 | 500.7 ± 70.7 | 409.5 ± 37.9 | 0.005 | 549.3 ± 10.6 | 412.2 ± 43.2 | 0.004 |
| Baseline ADMA, (μmol/L) | 0.56 ± 0.06 | 0.65 ± 0.08 | 0.56 ± 0.05 | 0.001 | 0.64 ± 0.09 | 0.55 ± 0.09 | <0.001 | 0.62 ± 0.11 | 0.56 ± 0.06 | 0.041 |
| 18–36 h post CABG ADMA, (μmol/L) | 0.95 ± 0.10 | 1.13 ± 0.17 | 0.93 ± 0.09 | 0.002 | 1.06 ± 0.16 | 0.93 ± 0.08 | 0.002 | 1.17 ± 0.14 | 0.93 ± 0.10 | 0.031 |
| 5–7 days post CABG ADMA, (μmol/L) | 0.75 ± 0.12 | 1.04 ± 0.12 | 0.73 ± 0.09 | <0.001 | 0.96 ± 0.15 | 0.73 ± 0.10 | 0.002 | 1.10 ± 0.06 | 0.74 ± 0.10 | 0.003 |
| Baseline β-TG, (IU/mL) | 58.8 ± 10.0 | 70.4 ± 12.6 | 56.9 ± 9.2 | 0.002 | 68.2 ± 12.5 | 56.7 ± 9.1 | <0.001 | 64.8 ± 15.3 | 57.5 ± 9.7 | 0.025 |
| 18–36 h post CABG β-TG, (IU/mL) | 84.6 ± 21.5 | 109.3 ± 28.2 | 82.6 ± 19.7 | 0.007 | 100.4 ± 26.9 | 82.6 ± 20.0 | <0.001 | 108.0 ± 24.2 | 83.5 ± 20.7 | <0.001 |
| 5–7 days post CABG β-TG, (IU/mL) | 68.5 ± 17.3 | 107.6 ± 16.7 | 65.8 ± 13.8 | <0.001 | 94.9 ± 24.1 | 66.1 ± 14.5 | 0.006 | 114.0 ± 15.0 | 66.7 ± 14.7 | 0.005 |
| Baseline WBC count, (×109/L) | 7.3 ± 2.1 | 8.8 ± 3.9 | 7.2 ± 1.9 | 0.009 | 8.2 ± 3.5 | 7.2 ± 1.9 | 0.252 | 8.2 ± 1.5 | 7.3 ± 2.2 | 0.215 |
| 18–36 h post CABG WBC count, (×109/L) | 10.6 ± 3.9 | 15.5 ± 7.2 | 10.1 ± 3.1 | 0.032 | 14.1 ± 6.3 | 10.0 ± 3.1 | 0.016 | 15.7 ± 5.9 | 10.5 ± 3.7 | 0.039 |
| Baseline CRP, (mg/L) | 2.5 (1.5–4.8) | 4.0 (1.8–9.1) | 2.4 (1.5–4.7) | 0.342 | 3.9 (1.7–8.9) | 2.4 (1.5–4.5) | 0.748 | 2.6 (2.4–8.2) | 2.4 (1.5–4.7) | 0.356 |
| 18–36 h post CABG CRP, (mg/L) | 160.5 (125.9–188.5) | 180.7 (170.9–258.8) | 152.9 (124.0–187.1) | 0.009 | 175.8 (170.6–230.2) | 152.8 (123.8–187.5) | 0.025 | 254.8 (201.4–256.2) | 153.1 (124.5–186.3) | 0.030 |
Values are displayed as mean ± standard deviation or median with 25th–75th percentiles inter-quartile range.
8-iso-PGF2α, 8-iso-prostaglandin F2α; ADMA, asymmetric dimethylarginine; β-TG, β-thromboglobulin; CABG, coronary artery bypass grafting; CPB, cardiopulmonary bypass; CRP, C-reactive protein; WBC, white blood counts.
Fig. 1Level changes of studied parameters in patients with and without CPB. No statistical differences, in terms of analyzed markers, were noted for the different types of CABG (on-pump CABG versus OPCAB). p Values are shown above the columns of the diagram.
8-iso-PGF2α, 8-iso-prostaglandin F2α; ADMA, asymmetric dimethylarginine; β-TG, β-thromboglobulin; CABG, coronary artery bypass grafting; OPCAB, off-pump coronary artery bypass surgery; CPB, cardiopulmonary bypass; CRP, C-reactive protein; pts., patients; WBC, white blood counts.